⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PSTV News
PLUS THERAPEUTICS, Inc. Common Stock
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
globenewswire.com
PSTV
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
globenewswire.com
PSTV
Form 8-K
sec.gov
PSTV
Form 8-K
sec.gov
PSTV
Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
globenewswire.com
PSTV
Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases
globenewswire.com
PSTV
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
globenewswire.com
PSTV
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
globenewswire.com
PSTV
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™
globenewswire.com
PSTV
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
PSTV